These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31712857)

  • 1. [Apalutamide for metastatic, castration-sensitive prostate cancer].
    Thomas C
    Urologe A; 2019 Dec; 58(12):1496-1497. PubMed ID: 31712857
    [No Abstract]   [Full Text] [Related]  

  • 2. [New treatment option-apalutamide for nonmetastatic, castration-resistant prostate cancer].
    Hadaschik B; Panic A
    Urologe A; 2018 Jun; 57(6):729-730. PubMed ID: 29789876
    [No Abstract]   [Full Text] [Related]  

  • 3. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
    Dror CM; Chi KN
    Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apalutamide for the treatment of patients with castration-resistant prostate cancer.
    Hauke R
    Drugs Today (Barc); 2018 Oct; 54(10):585-590. PubMed ID: 30398479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apalutamide shows efficacy in prostate cancer.
    Gourd E
    Lancet Oncol; 2018 Mar; 19(3):e149. PubMed ID: 29456088
    [No Abstract]   [Full Text] [Related]  

  • 6. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
    Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
    Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The modern treatment of metastatic castration-resistant prostate cancer].
    Küronya Z; Biró K; Maráz A; Géczi L
    Magy Onkol; 2019 Mar; 63(1):41-50. PubMed ID: 30889620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interstitial Lung Disease Caused by Apalutamide for Metastatic Castration-Sensitive Prostate Cancer.
    Del Castillo-Acuña R; Serradilla A; López-Campos F; Couñago F
    Arch Bronconeumol; 2024 Aug; 60(8):537-538. PubMed ID: 38705808
    [No Abstract]   [Full Text] [Related]  

  • 9. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
    Al-Salama ZT
    Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison.
    Nieto-Gómez P; Ubago-Pérez R; Cabeza-Barrera J
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):355-363. PubMed ID: 31133348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apalutamide: A new agent in the management of prostate cancer.
    May MB; Glode AE
    J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How I do it: Apalutamide use in non-metastatic castrate resistant prostate cancer.
    Moul JW
    Can J Urol; 2019 Jun; 26(3):9782-9786. PubMed ID: 31180310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis.
    Santoni M; Massari F; Rizzo A; Mollica V; Cimadamore A; Montironi R; Battelli N
    Tumori; 2023 Apr; 109(2):157-163. PubMed ID: 35593453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world prostate-specific antigen response and progression to castration-resistant prostate cancer among men with metastatic castration-sensitive prostate cancer treated with apalutamide: a multi-institutional study in the Chu-shikoku Japan Urological Consortium.
    Tohi Y; Kato T; Kobayashi K; Daizumoto K; Fukuhara H; Ohira S; Katayama S; Shimizu R; Takamoto A; Nishimura K; Ikeda K; Nagami T; Hayashida Y; Hirama H; Naito H; Tomida R; Sasaki Y; Yamamoto S; Shimizu S; Sugimoto M;
    Jpn J Clin Oncol; 2024 Feb; 54(2):167-174. PubMed ID: 37840362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study.
    Roy S; Saad F; Malone S; Agarwal N; Mohamad O; Morgan SC; Malone J; Swami U; Jia AY; Gebrael G; Mendiratta P; Brown JR; Rao SK; Sun Y; Wallis CJD; Chi KN; Chowdhury S; Kishan AU; Spratt DE
    Eur Urol; 2024 Apr; 85(4):398-400. PubMed ID: 38485300
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.
    Taneja SS
    J Urol; 2019 Oct; 202(4):661. PubMed ID: 31294666
    [No Abstract]   [Full Text] [Related]  

  • 17. Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
    Pérez-Ruixo C; Pérez-Blanco JS; Chien C; Yu M; Ouellet D; Pérez-Ruixo JJ; Ackaert O
    Clin Pharmacokinet; 2020 Feb; 59(2):229-244. PubMed ID: 31432469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Non-metastatic castration-resistant prostate cancer (M0CRPC) - Apalutamide in high-risk M0CRPC: case reports from the SPARTAN study and the apalutamide compassionate use program].
    Spiegelhalder P; Bögemann M
    Aktuelle Urol; 2022 Feb; 53(1):60-63. PubMed ID: 33882583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An evaluation of apalutamide for the treatment of prostate cancer.
    Boukovala M; Spetsieris N; Efstathiou E
    Expert Opin Pharmacother; 2020 Sep; 21(13):1537-1546. PubMed ID: 32543237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
    Dellis AE; Papatsoris AG
    Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.